Incidence and epidemiology
Primary cutaneous lymphomas (PCLs) are defined as nonHodgkin lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. After gastrointestinal lymphomas, PCLs are the second most common group of extranodal non-Hodgkin lymphomas, with an estimated annual incidence of 1/100 000 in Western countries. PCLs must be distinguished from nodal or systemic malignant lymphomas involving the skin secondarily, which often have another clinical behaviour, have a different prognosis and require a different therapeutic approach. In recent lymphoma classifications, PCLs are therefore included as separate entities. Within the group of PCLs, distinct types of cutaneous T cell lymphoma (CTCL) and cutaneous B cell lymphoma (CBCL) can be distinguished [1, 2] . In the Western world, CTCLs constitute $75%-80% of all PCLs [with mycosis fungoides (MF) as the most common type of CTCL] and CBCL $20%-25% [1] . However, different distributions have been observed in other parts of the world. In Southeast Asian countries, CTCLs other than MF [in particular Epstein-Barr virus-associated natural killer (NK)/T cell lymphomas] are much more common than in Western countries, while CBCLs are much more uncommon [3, 4] . PCLs are rare diseases and patients should ideally be seen by a multidisciplinary team of dermatologists, pathologists, haematologists and radiation oncologists.
Diagnosis and pathology/molecular biology
The diagnosis and classification of PCLs should always be based on a combination of clinical, histological, immunophenotypical and genetic data. Demonstration of clonal T cell receptor or immunoglobulin gene rearrangements in lesional skin or peripheral blood may be a valuable adjunct in selected cases. However, clinical and histopathological features are, in most cases, the most important deciding factors for therapeutic planning. PCLs should be classified according to the criteria of the revised 2017 World Health Organization (WHO) classification ( see Table 1 ) [2] .
Staging and risk assessment
In all cases, adequate staging should be carried out to exclude the presence of extracutaneous disease. Recommendations for the initial staging of patients with MF/Sézary syndrome (SS) are presented in Table 2 . Flow cytometry of the peripheral blood is usually recommended for all stages of MF. However, it is debatable whether this test is justified in patients who are not suspected to have SS. Computed tomography (CT) and/or fluorodeoxyglucose-positron emission tomography (FDG-PET) scans are optional in early-stage MF. Bone marrow examination is usually not indicated in patients with MF/SS.
Initial work-up for patients with a PCL other than MF/SS also includes complete physical examination, representative skin biopsy, complete and differential blood cell count, routine serum biochemistry with lactate dehydrogenase (LDH) and appropriate imaging studies (CT and/or FDG-PET scans) [5] . In PCLs with a predominantly subcutaneous presentation, such as subcutaneous panniculitis-like T cell lymphoma (SPTCL) and primary cutaneous gamma/delta T cell lymphoma (PCGD-TCL), FDG-PET is essential to evaluate the extent of disease. In patients with typical lymphomatoid papulosis (LyP) or primary cutaneous CD4 þ small/medium T cell lymphoproliferative disorder (LPD), CT and FDG-PET scans are not required. Bone marrow biopsy and aspirate should be carried out in cutaneous lymphomas with an intermediate or aggressive clinical behaviour but is not required in cutaneous lymphomas with an indolent clinical behaviour, unless indicated by other staging assessments [5, 6] . Bone marrow examination is not indicated in patients with primary cutaneous marginal zone lymphoma (PCMZL), but its significance in primary cutaneous follicle centre lymphomas (PCFCLs) is controversial [5, 7] . Prognosis is extremely variable depending on the type of PCLs and the stage of disease. For clinical staging of MF and SS, the revised tumour, node, metastasis and blood (TNMB) staging system should be used (Tables 3 and 4 ) [6] . Apart from clinical stage, older age, large cell transformation and increased LDH values have been identified as independent unfavourable prognostic factors in MF [8] [9] [10] . For PCLs other than MF/SS, a separate TNM classification system has been published [5] . This staging system is primarily meant to document extent of disease and cannot be used as a prognostic guide.
Treatment
The choice of treatment depends on the type of PCL and the stage of disease. Due to their heterogeneity and rarity, controlled clinical trials in PCLs are almost non-existent, with a few exceptions mainly concerning recently marketed drugs. Recommendations are therefore largely based on (retrospective) cohort studies and expert opinions discussed during consensus meetings of the European Organization of Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Group, the International Society for Cutaneous Lymphomas (ISCL), the United States Cutaneous Lymphoma Consortium (USCLC) and the International Lymphoma Radiation Oncology Group (ILROG), including consensus recommendations for clinical end points and response criteria in MF/SS [11] .
Mycosis fungoides and variants
Since early aggressive chemotherapy (ChT) is associated with considerable side effects but does not improve survival, a stageadapted conservative therapeutic approach is recommended for MF and its variants [12] [13] [14] [15] . Patients with only patches and/or plaques covering < 10% (stage IA) or ! 10% of the skin surface (stage IB) should be treated with skin-directed therapies, including topical steroids, psoralens plus ultraviolet A (PUVA), narrow-band ultraviolet B (nb-UVB) and topical cytostatic agents, such as mechlorethamine (nitrogen mustard) (Figure 1 ). nb-UVB is recommended for patients with patches or very thin plaques but PUVA is preferred for patients with thicker plaques [III, A] [13, 15] . Topical steroids can be recommended as monotherapy for stage IA disease with patches/flat plaques. In stage IB, þ relapsed or refractory MF, BV showed a 54% overall response rate (ORR) with a median time to response of 12 weeks and a median duration of response of 32 weeks in patients with MF, independent of the degree of CD30 expression [28] . Another phase II study reported an ORR of 70% in a group of 32 patients with relapsed or refractory MF/SS with a wide range of CD30 expression levels [29] . Results from a recent phase III trial, which compared BV to physician's choice of methotrexate (MTX) or bexarotene in 128 patients with relapsed or refractory CD30 þ CTCL, including 97 patients with MF, showed ORR lasting at least 4 months (ORR4) and complete response (CR) rate of 50% and 10%, respectively, in MF patients treated with BV compared with 10% and 0%, respectively, in the control group [30] . Median progression-free survival (mPFS) was 15.9 months in the BV group compared with 3.5 months in the control group.
In relatively young patients with refractory, progressive MF or with SS, allogeneic stem cell transplantation (alloSCT) should be considered. Durable responses have been reported, but experience is still limited and the optimal conditioning regimen and the optimal timing for an allogeneic transplant are currently IA  T1  N0  M0  B0-1  IB  T2  N0  M0  B0-1  IIA  T1-2  N1-2  M0  B0-1  IIB  T3  N0-2  M0  B0-1  III  T4  N0-2  M0  B0-1  IVA1  T1-4  N0-2  M0  B2  IVA2  T1-4  N3  M0  B0-2  IVB  T1-4  N0-3  M1  B0-2 MF, mycosis fungoides; SS, Sézary syndrome.
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Clinical Practice Guidelines [35] . An open-label multicentre randomised phase III study comparing mogamulizumab with vorinostat in 372 patients with relapsed or refractory MF or SS showed a significantly better ORR (28% versus 5%) and PFS (7.7 months versus 3.1 months) in the mogamulizumab group [36] .
Sé zary syndrome
SS is defined by a triad of erythroderma, generalised lymphadenopathy and the presence of clonally related neoplastic T cells with cerebriform nuclei (Sézary cells) in skin, lymph nodes and peripheral blood [1, 2] . Being a systemic disease (i.e. leukaemia) by definition, systemic treatment is required (Figure 1 ). Skin-directed therapies like PUVA or potent topical steroids may be used as adjuvant therapy. Extracorporeal photopheresis (ECP), either alone or in combination with other treatment modalities such as IFNa, retinoids, TSEBT and PUVA, has been suggested as the treatment of choice in SS and erythrodermic MF [IV, B] [13] [14] [15] . ORRs range from 30% to 80% with CR rates ranging from 14% to 25%, depending on the ECP regimen and the type of combination used. However, the suggested superiority of ECP over the traditional low-dose ChT regimens has not yet been substantiated by controlled randomised trials [37] . Prolonged treatment with a combination of low-dose chlorambucil and prednisone is often effective in controlling the disease but is unlikely to yield complete responses. Low-dose alemtuzumab ( [13, 15, 38] . It should be emphasised that comparison of treatment results in the different studies is almost impossible due to differences in diagnostic criteria used for SS.
Primary cutaneous CD30
1 lymphoproliferative disorders
The group of primary cutaneous CD30
þ LPDs includes primary cutaneous anaplastic large cell lymphoma (C-ALCL) and LyP, which form a spectrum of disease. Both C-ALCL and LyP have an excellent prognosis, with a 10-year survival of 90% and almost 100%, respectively [39] . LyP is clinically characterised by recurrent, self-healing papulonecrotic or papulonodular skin lesions. Since a curative therapy is not available and none of the available treatment modalities affects the natural course of the disease, in patients with relatively few non-scarring lesions, an expectant [39, 40, 42] . The ILROG suggests radiation with electrons, with bolus, a margin of ! 2 cm and a total dose of 24-30 Gy [18, 43] . In a recent study in 63 patients with C-ALCL, a total dose of 20 Gy in 8-10 fractions was found to be effective and well-tolerated in patients presenting with solitary or localised skin lesions. For patients with multifocal or relapsing skin lesions, a radiation dose of 8 Gy (2 Â 4 Gy) was suggested [44] . Recent studies report high response rates of BV in patients with primary cutaneous CD30 þ lymphoproliferations [28] [29] [30] . In the phase III trial, which compared BV to physician's choice of MTX or bexarotene, BV showed an ORR4 and CR rate of 75% and 31%, respectively, in C-ALCL patients treated with BV compared with 20% and 7%, respectively, in the control group [30] . BV should be considered in cases with multifocal skin lesions refractory to conventional therapies and in patients developing extracutaneous disease [II, B] [42] . Multi-agent ChT is only indicated in patients presenting with or developing extracutaneous disease and in rare patients with rapidly progressive skin disease [39, 40] .
Subcutaneous panniculitis-like T cell lymphomas
The term SPTCL is only used for cases with an a/b T cell phenotype, which have a favourable prognosis, particularly if not associated with a haemophagocytic syndrome (HPS), which is frequently an extremely aggressive clinical syndrome requiring immediate intervention. One study reported 5-year overall survival (OS) rates of 91% and 46% in SPTCL patients without and with an HPS, respectively [45] . In SPTCL without associated HPS, systemic steroids or other immunosuppressive agents (ciclosporin, MTX) should be considered first; in cases of solitary skin lesions, RT with electrons is advised [IV, A]. Little information on radiation dose is available, but a dose of 40 Gy has been used. Bexarotene may be also effective in SPTCL [46] . Multi-agent ChT is required only in cases with progressive disease not responding to immunosuppressive therapy and in cases with HPS.
Primary cutaneous extranodal NK/T cell lymphoma, nasal type
Primary cutaneous extranodal NK/T cell lymphoma, nasal type is an Epstein-Barr virus-associated type of lymphoma with an aggressive clinical behaviour, which is very rare in Western countries, but more common in Asia and Central and South America [2] . The skin is the second most common site of involvement after the nasal cavity/nasopharynx and, in some patients, skin lesions may be the only manifestation of disease [47] [48] [49] . Patients presenting with only localised skin lesions (stage IE) have a somewhat better prognosis than localised lesions in non-cutaneous sites [48, 49] . In rare cases with small, solitary lesions, RT alone can be considered, as longterm disease control has been achieved with this approach in some reported cases [V, C] [50] [51] [52] . This is also the option for older or frail patients who cannot tolerate intensive ChT. In general, however, combined modality treatment with L-asparaginase containing ChT, such as SMILE (dexamethasone, methotrexate, ifosfamide, Lasparaginase and etoposide) is the preferred mode of treatment, combined with RT, for localised disease, as it is for nasal NK/T cell lymphomas, although there is still a paucity of data on the outcome of this treatment in primary cutaneous NK/T cell lymphoma [V, B] [53] . Recommended radiation doses are higher than for other lymphomas, with 50 Gy to the initial lesion and a boost of 5-10 Gy to residual disease [IV, A] [18] . In patients presenting with generalised skin lesions, the disease shows an aggressive clinical behaviour and should be treated as other patients with stage II-IV disease [53] .
Primary cutaneous peripheral T cell lymphoma-not otherwise specified
Within the group of primary cutaneous peripheral T cell lymphoma-not otherwise specified (PTCL-NOS), four somewhat better-defined subgroups have been included as (provisional) entities (see Table 1 ) [1, 2] . These include PCGD-TCL, primary cutaneous aggressive epidermotropic CD8 þ cytotoxic T cell lymphoma (CD8 þ AECTCL), primary cutaneous CD4 þ small/medium T cell LPD and primary cutaneous acral CD8 þ T cell lymphoma. For cases that do not fit into one of the well-defined types of CTCL, including these rare subtypes, the term primary cutaneous PTCL-NOS is maintained. Both PCGD-TCL and CD8
þ AECTCL have in common a generally aggressive clinical course and poor prognosis, and should therefore be managed according to the ESMO guidelines for PTCL-NOS [53] . Patients with primary cutaneous CD4 þ small-medium T cell LPD and patients with a primary cutaneous acral CD8 
Cutaneous B cell lymphoma
In the WHO-EORTC classification, three main types of CBCL are distinguished: PCMZL, PCFCL and primary cutaneous diffuse large B cell lymphoma, leg type (PCLBCL-LT). PCMZL and PCFCL are indolent types of CBCL with a disease-related 10-year-survival exceeding 90%, while PCLBCL-LT has a more unfavourable prognosis (disease-related 5-year survival, approximately 50%). EORTC/ISCL consensus recommendations for the management of these three types of CBCL have been formulated and are, with minor modifications, presented in Figures rituximab as a single drug may achieve remissions. PCLBCL-LT has the phenotype and gene expression profile of ABC-type diffuse large B cell lymphoma (DLBCL) and shows a high frequency of MYD88 and CD79B mutations, which results in constitutive activation of nuclear factor kappa light chain enhancer of activated B cells (NF-jB) signalling [55] . Recent studies suggest that PCLBCL-LT patients may benefit from treatment with Bruton's tyrosine kinase (BTK) inhibitors, which block the NF-jB pathway [56] .
Personalised medicine
Personalised approaches in the treatment of PCL are still limited. BV is used for the treatment of advanced stage refractory or relapsed CD30 þ CTCL, including both patients with C-ALCL and patients with MF/SS, also with the purpose of bridging eligible patients to an alloSCT [28] [29] [30] 33] . Mogamulizumab is a humanised monoclonal antibody targeting the CC chemokine receptor 4 (CCR4), which is overexpressed on the malignant T cells in MF/SS. Mogamulizumab has shown significant clinical efficacy in MF/SS, particularly in patients with blood involvement [34] [35] [36] . PCLBCL-LT frequently shows MYD88 and CD79B mutations, resulting in constitutive NF-jB activation [55] . The efficacy of BTK inhibitors that target this pathway is currently under investigation but reports on their efficacy in CBCL are still scarce [56] .
Follow-up, long-term implications and survivorship
Follow-up recommendations should be individualised depending on the clinical situation. The frequency of follow-up visits depends on the type of PCL and the stage of disease. It may vary from every 6 or 12 months in patients with indolent types of PCL and stable disease or patients in complete remission to every 4-6 weeks in patients with active or progressive disease. Follow-up visits should focus on history and physical examination, and additional testing (histology, blood examination, imaging, etc.) should only be carried out if required. Routine imaging after treatment is not required, since tumour responses are visible to the naked eye and in most instances, recurrences are also localised in the skin. Survivorship issues are poorly studied in PCLs and are probably similar to those of patients with more common lymphomas with the same prognosis treated similarly. A long-term implication specifically found in PCL patients is the increased risk for developing skin cancers, in particular squamous cell carcinomas, following long-term treatment with PUVA.
Methodology
These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical
Primary cutaneous peripheral T cell lymphoma -not otherwise specified • PCGD-TCL and primary cutaneous CD8 þ AECTCL are aggressive types of CTCL, which should be managed as systemic PTCL-NOS Practice Guidelines development, http://http://www.esmo.org/ Guidelines/ESMO-Guidelines-Methodology. The relevant literature has been selected by the expert authors. A summary of recommendations is shown in Table 5 . Levels of evidence and grades of recommendation have been applied using the system shown in Table 6 . Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty. This manuscript has been subjected to an anonymous peer review process.
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